BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30323247)

  • 1. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr
    Bijnen M; Beelen N; Wetzels S; Gaar JV; Vroomen M; Wijnands E; Scheijen JL; van de Waarenburg MPH; Gijbels MJ; Cleutjens JP; Biessen EAL; Stehouwer CDA; Schalkwijk CG; Wouters K
    Sci Rep; 2018 Oct; 8(1):15256. PubMed ID: 30323247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice.
    Jeurissen ML; Walenbergh SM; Houben T; Hendrikx T; Li J; Oligschlaeger Y; van Gorp PJ; Gijbels MJ; Bitorina A; Nessel I; Radtke F; Vooijs M; Theys J; Shiri-Sverdlov R
    PLoS One; 2016; 11(11):e0167199. PubMed ID: 27898698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.
    Wu J; Zhao MY; Zheng H; Zhang H; Jiang Y
    Acta Pharmacol Sin; 2010 Oct; 31(10):1367-75. PubMed ID: 20835270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible?
    Lytle KA; Jump DB
    PLoS One; 2016; 11(1):e0146942. PubMed ID: 26761430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
    Allam MM; El Gazzar WB
    Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk.
    van den Hoek AM; de Jong JCBC; Worms N; van Nieuwkoop A; Voskuilen M; Menke AL; Lek S; Caspers MPM; Verschuren L; Kleemann R
    Metabolism; 2021 Nov; 124():154873. PubMed ID: 34478753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
    van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis.
    Bashiri A; Nesan D; Tavallaee G; Sue-Chue-Lam I; Chien K; Maguire GF; Naples M; Zhang J; Magomedova L; Adeli K; Cummins CL; Ng DS
    Biochim Biophys Acta; 2016 Jul; 1861(7):594-605. PubMed ID: 27090939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
    Lytle KA; Wong CP; Jump DB
    PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.
    Wouters K; van Gorp PJ; Bieghs V; Gijbels MJ; Duimel H; Lütjohann D; Kerksiek A; van Kruchten R; Maeda N; Staels B; van Bilsen M; Shiri-Sverdlov R; Hofker MH
    Hepatology; 2008 Aug; 48(2):474-86. PubMed ID: 18666236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
    Fernando DH; Forbes JM; Angus PW; Herath CB
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease.
    Bieghs V; Van Gorp PJ; Wouters K; Hendrikx T; Gijbels MJ; van Bilsen M; Bakker J; Binder CJ; Lütjohann D; Staels B; Hofker MH; Shiri-Sverdlov R
    PLoS One; 2012; 7(1):e30668. PubMed ID: 22295101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.